Advances in engineering and clinical translation of human iPSC‑derived natural killer cells

Chimeric antigen receptor (CAR)-expressing autologous T cells provide potentially curative therapy for certain hematological malignancies; however, this treatment is constrained by logistical challenges, high costs, and toxicity risks that require close monitoring. Furthermore, the efficacy of autologous CAR‑T cells remains limited in the solid tumor setting due to  issues that include antigen heterogeneity and the immunosuppressive tumor microenvironment. This review explores the use of induced pluripotent stem cell‑derived natural killer (iPSC‑NK) cells as an allogeneic cell therapy platform that addresses these unmet needs through standardized, scalable manufacturing and improved safety. Human iPSCs provide a renewable, clonally defined cell population that is amenable to multiplexed genetic engineering, including precise integration of functional enhancements. NK cells can be routinely produced at clinical‑scale from these gene edited iPSCs to provide a safe, effective, and widely accessible cell‑based immunotherapy.

iPSC-derived NK cells offer a safer, scalable alternative to CAR-T therapy — addressing toxicity, manufacturing complexity, and poor solid tumor efficacy.

What you will learn

01

Why NK cells are safer allogeneic effectors than T cells

02

How iPSC engineering overcomes persistence, rejection, and tumor infiltration

03

The clinical progress of iPSC-NK therapies and their expanding indications

The iPSC-NK cell platform

1

iPSC master cell bank

2

Multiplexed gene editing

3

NK cell differentiation & expansion

4

Off-the-shelf cryopreserved product

Key findings

A single iPSC master cell bank provides limitless, uniform NK cell production with stable multiplexed gene edits

NK-optimized CARs, IL-15 engineering, and immune evasion strategies address persistence, host rejection, and tumor infiltration

Early trials show no grade 3+ CRS or ICANS and >50% response rates in B cell lymphoma

Key interests

iPSCs

NK Cell Therapy

Cell & Gene Therapy

Cancer Immunotherapy

Allogeneic Therapies

Please enter your email to access content Read now